SCHEMBL4324693

SCHEMBL4324693

CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)CC(=O)N1C

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 15/20 0.54
CYP3A4 P08684 6/20 0.54
CYP2D6 P10635 6/20 0.54
RPS6KB1 P23443 6/20 0.54
RPS6KA1 Q15418 6/20 0.54
CYP2C9 P11712 2/20 0.54
ROCK2 O75116 1/20 0.49
GPBAR1 Q8TDU6 1/20 0.38
GRK2 P25098 5/20 0.38
GRK5 P34947 2/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
LRRK2 Q5S007 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884743 0.90 ROCK1 (0.59) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3884931 0.89 ROCK1 (0.60) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3860919 0.88 ROCK1 (0.54) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3885111 0.85 ROCK1 (0.68) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3893789 0.82 ROCK1 (0.73) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3885385 0.77 ROCK1 (0.57) ROCK1RPS6KB1RPS6KA1ROCK2GRK2
SCHEMBL4934586 0.77 ROCK1 (0.74) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3887046 0.77 JAK2 (0.40) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL3887155 0.77 LRRK2 (0.43) ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1
SCHEMBL4313069 0.76 GPBAR1 (0.42) CYP3A4GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592357-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US claimed
US-20080058384-A1 Novel Compounds GLAXOSMITHKLINE LLC 2008-03-06 US claimed
US-7592357-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592357-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592357-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-20080058384-A1 Novel Compounds GLAXOSMITHKLINE LLC 2008-03-06 US disclosed
US-20080058384-A1 Novel Compounds GLAXOSMITHKLINE LLC 2008-03-06 US disclosed
US-20080058384-A1 Novel Compounds GLAXOSMITHKLINE LLC 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058384-A1 Novel Compounds ARHGDIB, TNK2, ROCK2 ROCK1 6/4885CYP3A4 4653/4885CYP2D6 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.